<div id="readability-page-1"><div><p>EVERY chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight.</p><p>Among the lessons from 2025, however, is that runaway success is not all upside. As the experience of whizzy chatbots, weight-loss jabs and wacky dolls illustrates, it brings problems, too.</p><p>The first pitfall is that bosses face the vexed task of scaling up their business to satisfy a level of demand that is impossible to predict.</p></div></div>

OpenAI

诺和诺德公司

泡泡玛特

<p>每位首席执行官都梦想着这一点：一款产品如此成功，以至于让他们的公司在一夜之间从默默无闻跃升为超级明星。然而，从 2025 年的经验中可以看出，突飞猛进的成功并非全是好事。正如炫酷的聊天机器人、减肥注射剂和奇特玩偶的经历所示，这也带来了问题。第一个陷阱是，老板们面临着一个棘手的任务，即扩大业务以满足一个无法预测的需求水平</p>

What Novo Nordisk, OpenAI and Pop Mart have in common

- 成功产品可使公司迅速崛起，但也带来问题。  
- 难以预测的需求使高管面临扩张挑战。  
- 2025 年的教训表明，成功并非全是好处。

诺和诺德公司、OpenAI 和泡泡玛特有什么共同点